StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Not quite break even but close

<< Previous

Bullboard Posts

Next >>

Comment by TrippinAgain01on Nov 15, 2022 8:22am

86 Views

Post# 35099165

RE:RE:Not quite break even but close

At this rate, SZLS may gain traction in the market by 2058 lol, talk about moving at a snails pace. If SZ had any common sense they would get a large company on board to legitimize Aristotle, but we all know this product is more than likely to be fake. If it really is what they claim it is, why after 20 months does not a single company want to join with them? Notice how the Aristotle sales numbers are hidden again. Of coarse the paid pumpers will try to act like things are going in the right direction lol so funny...

User image